Krystal Biotech (KRYS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 May, 2026Opening remarks and agenda
Meeting called to order by Chairman and CEO, with introductions of key officers and instructions for submitting questions during the session.
Secretary confirmed mailing of meeting materials and availability of proxy statement and annual report.
Board and executive committee updates
Two nominees, Krish Krishnan and Christopher Mason, were presented for election as directors to serve until 2029.
Shareholder proposals
Four proposals were presented: election of directors, ratification of KPMG LLP as auditor, approval of executive compensation, and approval of non-employee director compensation policy.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Krystal Biotech
- Global VYJUVEK expansion and pivotal pipeline data set the stage for major growth ahead.KRYS
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue and profit surged, with strong margins and major clinical milestones ahead.KRYS
Q1 20264 May 2026 - Global launches and pipeline advances drive growth, with key milestones expected in 2026.KRYS
44th Annual J.P. Morgan Healthcare Conference15 Apr 2026 - Proxy covers director elections, auditor ratification, pay, and new director compensation policy.KRYS
Proxy filing3 Apr 2026 - Key votes include director elections, auditor ratification, and compensation approvals.KRYS
Proxy filing3 Apr 2026 - Strong revenue growth and pipeline progress position the company for major milestones in 2026.KRYS
Corporate presentation16 Mar 2026 - ROW sales and pivotal trial progress position the company for strong 2026 growth.KRYS
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Record revenue and net income growth, global expansion, and major pipeline progress in 2025.KRYS
Q4 202517 Feb 2026 - Q3 2025 delivered $97.8M revenue, 96% margin, and global VYJUVEK expansion, boosting net income.KRYS
Q3 20253 Feb 2026